For Industry
Generic Drug User Fee Amendments of 2012
GDUFA, a historic first: Providing user fees for FDA to ensure timely review of applications for generic drugs
The Generic Drug User Fee Amendments of 2012 (GDUFA) is designed to speed access to safe and effective generic drugs to the public and reduce costs to industry. The law requires industry to pay user fees to supplement the costs of reviewing generic drug applications and inspecting facilities. Additional resources will enable the Agency to reduce a current backlog of pending applications, cut the average time required to review generic drug applications for safety, and increase risk-based inspections.
GDUFA is designed to build on the success of the Prescription Drug User Fee Act (PDUFA). Over the past 20 years, PDUFA has ensured a more predictable, consistent, and streamlined premarket program for industry and helped speed access to new, safe and effective prescription drugs for patients. GDUFA will also enhance global supply chain safety by requiring that generic drug facilities and sites around the world self-identify.
What's New
2013 GDUFA and You Conference
6/12-13/2013 (Tentative Dates)Generic Drug Regulatory Science Initiatives Public Meeting: June 21, 2013 GDUFA Facility Arrears List (PDF - 22KB)
5/16/2013
Self-Identification of Generic Drug Facilities, Sites and Organizations
Fiscal year 2014 reporting period for self-identification closes June 1, 2013
Self-Identification of Generic Drug Facilities, Sites and Organizations
Frequently Asked Questions- Self Identified Facilities List (XLS - 2.5MB)
(updated 5/17/2013) Federal Register Notice: Generic Drug Facilities, Sites, and Organizations
4/16/2013- Technical Walk-Through and Live Question and Answer Session
11/19/2012 and 11/20/2012 - Overview and Technical Walk-Through of Self-Identification Process
9/21/2012







